Isolated polypeptides of cd44 and uses thereof

Abstract

Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.

What is claimed is: 
     
         1 . A method of treating an inflammatory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a 5 amino acid peptide consisting of SEQ ID NO: 1, thereby treating the inflammatory disease in the subject. 
     
     
         2 . A method of treating an inflammatory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a 5 amino acid peptide modified at the N— and/or C— terminus, wherein the peptide consists of SEQ ID NO: 1 and has an anti-inflammatory activity, thereby treating the inflammatory disease in the subject. 
     
     
         3 . The method of  claim 2 , wherein said peptide is modified at the N terminus with an Acetyl. 
     
     
         4 . The method of  claim 2 , wherein said peptide is modified at the C terminus with an Amide. 
     
     
         5 . The method of  claim 2 , wherein said peptide is modified at the N-terminus with an Acetyl and at the C-terminus with an Amide as set forth in SEQ ID NO: 4. 
     
     
         6 . The method of  claim 1 , wherein said peptide is attached to a non-proteinaceous moiety. 
     
     
         7 . The method of  claim 6 , wherein said attached is covalent attachment. 
     
     
         8 . The method of  claim 2 , wherein said peptide is attached to a non-proteinaceous moiety. 
     
     
         9 . The method of  claim 8 , wherein said attached is covalent attachment. 
     
     
         10 . The method of  claim 2 , wherein said anti-inflammatory activity is not dependent on vaccination or mucosal tolerance. 
     
     
         11 . The method of  claim 2 , wherein said peptide is capable of binding a protein selected from the group consisting of serum amyloid A, Transthyretin and apolipoprotein B. 
     
     
         12 . The method of  claim 1 , wherein said administering comprises oral administering. 
     
     
         13 . The method of  claim 2 , wherein said administering comprises oral administering. 
     
     
         14 . The method of  claim 1 , wherein said inflammatory disease is a neurodegenerative disease. 
     
     
         15 . The method of  claim 2 , wherein said inflammatory disease is a neurodegenerative disease. 
     
     
         16 . The method of  claim 1 , wherein said inflammatory disease is cancer. 
     
     
         17 . The method of  claim 2 , wherein said inflammatory disease is cancer.